Aerocrine files patent infringement suit against Medisoft in Germany

Aerocrine files patent infringement suit against Medisoft in Germany

SOLNA, Sweden - 20 March 2008 - Aerocrine AB (OMX Nordic Exchange: AERO) today
announced the filing with the District Court of Dusseldorf of a Complaint and
Motion to prevent Medisoft, P.A.E from marketing and selling its exhaled Nitric
Oxide (NO) analyser in Germany.  The claim seeks both an injunction and damages.

Medisoft P.A.E. is a Belgian company that recently began marketing and selling
the Hypair exhaled NO analyser in Germany.  Aerocrine claims the Medisoft Hypair
Analyser infringes four of Aerocrine's European patents.  They are EP Nos.
0,606,351; 0,724,623; 1,439,781; and 1,545,305.

”Aerocrine´s view is that Medisoft's product Hypair uses Aerocrine's proprietary
technology”, says Paul de Potocki, CEO of Aerocrine AB. “We welcome other
companies to join Aerocrine in bringing the benefits of inflammation monitoring
to patients and care providers, but we will defend our company's patents
resolutely”.

For more information, contact:

Paul de Potocki, CEO
Telephone: +46 8 629 07 82

About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in the technology to monitor and manage airway inflammation, Aerocrine
markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
2.00 pm on March the 20th 2008.